Bromfenac alone or with single intravitreal injection of bevacizumab or triamcinolone acetonide for treatment of uveitic macular edema

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 251, Issue 7, 2013, Pages 1801-1806

  Radwan, Alaa E ^a,b   Arcinue, Cheryl A ^a,b   Yang, Paul ^a,b   Artornsombudh, Pichaporn ^a,b   Abu Al Fadl, Esam M ^d   Foster, C Stephen ^a,b,c  

^a MASSACHUSETTS EYE RESEARCH AND SURGERY INSTITUTION   (United States)

^b Massachusetts Eye Research and Surgery Institute   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d Sohag University   (Egypt)

Author keywords

Bevacizumab; Bromfenac; Macular edema; Triamcinolone acetonide

Indexed keywords

BEVACIZUMAB; BROMFENAC; TRIAMCINOLONE; TRIAMCINOLONE ACETONIDE;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; MACULAR THICKNESS; MAJOR CLINICAL STUDY; MALE; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETINA MACULA EDEMA; SINGLE DRUG DOSE; UVEITIS; VISUAL ACUITY;

ANGIOGENESIS INHIBITORS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL, HUMANIZED; BENZOPHENONES; BROMOBENZENES; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; RETREATMENT; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TRIAMCINOLONE ACETONIDE; UVEITIS; VISUAL ACUITY;

EID: 84879203443     PISSN: 0721832X     EISSN: 1435702X     Source Type: Journal    
DOI: 10.1007/s00417-013-2309-4     Document Type: Article

References (22)

1. Prito JF, Dios E, Gutierrez JM, Mayo A, Calonge M, Herreras JM (2001) Pars planitis: epidemiology, treatment, and association with multiple sclerosis. Ocul Immunol Inflamm 9:93-102
2. Markomichelakis NN, Halkiadakis I, Pantelia E, Peponis V, Patelis A, Theodossiadis P, Theodossiadis G (2004) Patterns of macular edema in patient with uveitis. Qualitative and quantitative assessment using optical coherence tomography. Ophthalmology 111:946-953
3. Rothova A, Suttorp-van Schulten MS, Frits Treffers W, Kijlstra A (1996) Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol 80:332-336
4. Papadaki T, Zacharopoulos I, Iaccheri B, Fiore T, Foster CS (2005) Somatostatin for uveitic cystoid macular edema (CME). Ocul Immunol Inflamm 13:469-470
5. Flach AJ, Stegman RC, Graham J, Kruger LP (1990) Prophylaxis of aphakic cystoid macular edema without corticosteroids. A paired-comparison, placebo-controlled double-masked study. Ophthalmology 97:1253-1258
6. Rho DS (2003) Treatment of acute pseudophakic cystoid macular edema: diclofenac versus ketorolac. J Catract Refractive Surg 29:2378-2384
7. Hariprasad SM, Akduman L, Clever JA, Ober M, Recchia FM, Mieler WF (2009) Treatment of cystoid macular edema with the new-generation NSAID nepafenac 0.1 %. Clin Ophthalmol 3:147-145
8. Kim SJ, Flach AJ, Jampol LM (2010) Nonsteroidal anti-inflammatory drugs in ophthalmology. Surv Ophthalmol 55:108-133
9. Cordero Coma M, Sobrin L, Christen W, Foster CS (2007) Intravitreal bevacizumab for treatment of uveitic macular edema. Ophthalmology 114:1574-1579
10. Antcliff RJ, Spalton DJ, Stanford MR, Graham EM, Ffytche TJ, Marshall J (2001) Intravitreal triamcinolone for uveitic cystoid maculare edema: an optical coherence tomography study. Ophthalmology 108:765-772
11. Tranos PG, Tsaousis KT, Vakalis AN, Asteriades S, Pavesio CE (2012) Long-term follow-up of inflammatory cystoid macular edema. Retina(Apr 4)
12. Jones J, Francis P (2009) Ophthalmic utility of topical bromfenac, a twice-daily nonsteroidal anti-inflammatory agent. Expert Opin Pharmacother 10:2379-2385
13. Endo N, Kato S, Haruyama K, Shoji M, Kitano S (2010) Efficacy of bromfenac sodium ophthalmic solution in preventing cystoid macular oedema after cataract surgery in patients with diabetes. Acta Ophthalmol 88:896-900
14. Henderson BA, Gayton JL, Chandler SP, Gow JA, Klier SM, McNamara TR, Bromfenac Ophthalmic Solution (Bromday) Once Daily Study Group (2011) Safety and efficacy of bromfenac ophthalmic solution (Bromday) dosed once daily for postoperative ocular inflammation and pain. Ophthalmology 118:2120-2127
15. Kok H, Lau C, Maycock N, McClusky P, Lightman S (2005) Outcome of intravitreal triamcinolone in uveitis. Ophthalmology 112:1916.e1-7
16. Antonio B, Russo V, Prascina F, Delle Noci N (2009) Short-term safety and efficacy of intravitreal bevacizumab for pseudophakic cystoid macular edema. Retina 29:33-37
17. Soheilian M, Rabbanikhah Z, Ramezani A, Kiavash V, Yaseri M, Peyman GA (2010) Intravitreal bevacizumab versus triamcinolone acetonide for refractory uveitic cystoid macular edema: a randomized pilot study. J Ocul Pharmacol Ther 26:199-206
18. Bae JH, Lee CS, Lee SC (2011) Efficacy and safety of intravitreal bevacizumab compared with intravitreal and posterior sub-tenon triamcinolone acetonide for treatment of uveitic cystoid macular edema. Retina 31:111-118
19. Lasave AF, Zeballos DG, El-Haig WM, Diaz-Llopis M, Salom D, Arevalo JF (2009) Short-term results of a single intravitreal bevacizumab (avastin) injection versus a single intravitreal triamcinolone acetonide (kenacort) injection for the management of refractory noninfectious uveitic cystoid macular edema. Ocul Immunol Inflamm 17:423-430
20. Maca SM, Abela-Formanek C, Kiss CG, Sacu SG, Benesch T, Barisani-Asenbauer T (2009) Intravitreal triamcinolone for persistent cystoid macular oedema in eyes with quiescent uveitis. Clin Experiment Ophthalmol 37:389-396
21. Spitzer MS, Ziemssen F, Yoeruek E, Petermeier K, Aisenbrey S, Szurman P (2008) Efficacy of intravitreal bevacizumab in treating postoperative pseudophakic cystoid macular edema. J Cataract Refract Surg 34:70-75
22. Cervantes-Castañeda RA, Giuliari GP, Gallagher MJ, Yilmaz T, MacDonell RE, Quinones K, Foster CS (2009) Intravitreal bevacizumab in refractory uveitic macular edema: 1-year follow-up. Eur J Ophthalmol 19:622-629